0QAVNanobiotix S.A.

LSE · GB · Healthcare · Biotechnology · nanobiotix.com

37.31EUR-0.17%Mkt Cap: —P/E: —3d ago

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous …

Key Statistics

Company

Market Cap—

Enterprise Value2.01B $

Revenue (TTM)35.43M $

Gross Profit35.43M $

Net Income (TTM)-26.04M $

Revenue/Share0.7413 USD

Last Price37.31 EUR

Fiscal Year EndDec 2025

MR QuarterDec 2025

Employees100

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-176.20

EV/Revenue56.70

P/S—

P/B-21.37

EPS (TTM)-1.35

EPS (Forward)—

52W Range

34.2054% of range39.98

52W High39.98 EUR

52W Low34.20 EUR

Profitability

Gross Margin100.00%

Oper. Margin-196.42%

EBITDA Margin-32.18%

Profit Margin-73.52%

ROE—

ROA-10.06%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-36.33M $

CapEx (TTM)—

FCF Margin-24.22%

FCF Yield—

Net Debt46.27M $

Net Debt/EBITDA-4.06

Balance Sheet

Debt/Equity—

Current Ratio1.09

Quick Ratio1.05

Book Value/Sh-1.7460 EUR

Cash/Share1.090 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 EUR

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.19.61M

Float31.95M

Insiders15.55%

Institutions36.13%

Technical

SMA 506.677 (+458.8%)

SMA 2006.545 (+470.1%)

Beta0.57

S&P 52W Chg19.18%

Avg Vol (30d)17.63K

Avg Vol (10d)1.94K

Technical Indicators

RSI (14)61.5

MACD1.1801

MACD Signal0.8335

MACD Hist.+0.3467

BB Upper38.22 EUR

BB Middle34.28 EUR

BB Lower30.34 EUR

BB Width22.99%

ATR (14)2.282 EUR

Vol Ratio (20d)1.47x

0QAVNanobiotix S.A.

Industry Peers

Key Statistics